GHRP-6 Review | Buy Ghrp-6 Peptide
30NovNovember 30, 2019
GHRP-6 Review | Buy Ghrp-6 Growth Hormone Releasing Peptide
Clinical research is the backbone of modern medical intervention. At Loti Labs, we acknowledge this and are strategically equipped to making this happen. We are a USA based peptide and research company and we stock USA made GHRP-6 for sale for research purposes only. Our products are not formulated for human consumption.
Understanding GHRP-6: Growth Hormone Uses, Effects, and Research Applications
Growth hormone-releasing peptide-6 is a synthetic hexapeptide and a met-enkephalin derivative that contains a chain of 6 unnatural D amino acids namely L-Histidine, D-Tryptophan, L-Alanine, L-Tryptophan, D-Phenylalanine and L-Lysine. It is the first hexapeptide studied in animal test subjects and was identified more than a decade ago.
It belongs in the family of the Human Growth Hormone secretagogue, a substance that causes secretion of a separate substance. GHRP-6 has no structural similarity with Growth Hormone Releasing Hormone (GHRH) and works utilizing specific receptors present at the pituitary or hypothalamic level. Studies showed that GHRP-6 receptors are also present in different peripheral tissues such as the heart, adrenal, ovary, testis, lung and skeletal muscle. GHRP-6 plays a role in preserving the structural integrity of cardiac muscle and protecting myocardial cells from damage, particularly in conditions like doxorubicin-induced cardiotoxicity.
The cytoprotective effects of GHRP-6 are non-growth Hormone-related which include neuroprotective, cardioprotective, anti-inflammatory as well as hepatoprotective effects.
Currently, GHRP-6 is not approved for therapeutic use in the United States.
What is GHRP-6?
GHRP-6, also known as growth hormone-releasing peptide-6, is a small molecular weight peptide that plays a crucial role in stimulating the release of growth hormone (GH) from the pituitary gland. This synthetic peptide mimics the action of ghrelin, a natural hormone produced by the stomach that triggers GH release. By binding to ghrelin receptors, GHRP-6 effectively promotes the secretion of growth hormone, which is essential for various physiological processes.
Beyond its role in growth hormone release, GHRP-6 has demonstrated significant cardioprotective effects. Research indicates that it can be utilized to prevent or mitigate cardiotoxicity induced by certain chemotherapeutic agents, such as doxorubicin. This makes GHRP-6 a valuable peptide in the realm of medical research, particularly in studies focused on cardiac health and growth hormone-related therapies.
Historical Appraisal of GHRP-6
The journey of GHRP-6 began in the 1990s when it was first synthesized as part of a research initiative aimed at developing novel treatments for growth hormone deficiency. Since its inception, GHRP-6 has been the subject of extensive research, with numerous studies exploring its effects on GH release and its potential therapeutic applications.
GHRP-6 has been shown to stimulate growth hormone release in both healthy individuals and those with GH deficiency. Its ability to enhance GH secretion has led to its use in treating various conditions, including growth hormone deficiency, Turner syndrome, and Prader-Willi syndrome. The peptide’s efficacy in these areas underscores its importance in medical research and its potential for broader therapeutic applications.
Understanding the Chemical Structure of GHRP-6 Small Molecular Weight Peptide
Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
465612
Molecular weight: 873 g/mol
CAS number: 87616-84-0
MECHANISM OF ACTION
Studies in animal test subjects show that GHRP-6 stimulates Ghrelin, “the hunger hormone” through its ghrelin receptor which in turn signals an increased production of growth hormone (GH) by acting at the level of the pituitary or hypothalamus through a specific receptor different from that of the endogenous Growth Hormone-Releasing Hormone (GHRH). The GH response observed in various experimental setups highlights the differences in GH levels following the administration of GHRP-6 and GHRH in both diabetic and control subjects. The effects of GHRP-6 on GH release were achieved using various doses and administration routes.
The liver produces Insulin-like Growth Factor-1 (IGF-1) in response to the secretion of the growth hormone, which is essential in preventing cell death and promoting cell proliferation. IGF-1 is vital for achieving maximum growth. Growth hormone secretagogues (GHS), including ghrelin, play a crucial role in modulating GH secretion by interacting with pituitary and hypothalamic receptors.
The four important parts of the test subjects that demonstrate the role of GHRP-6 include the pituitary gland, central nervous system, liver, and stomach.
GHRP-6 EFFECTS
GHRP-6 study was carried out on animal test subjects and these studies show that peptides could have several theoretical benefits by its action of increasing the secretion of growth hormone from the pituitary gland and mimicking the hunger hormone ghrelin, known to protect neurons. These benefits include:
A decrease in body fat
Increase in muscle growth
Increase in bone tissue growth
Increase in immunity
Improvement in sleep
Reduction in heart problems
Improvement in brain function
Timely healing of injuries
Improvement in skin appearance by smoothing wrinkles
In a notable study, GHRP-6 was found to reduce myocardial necrosis with statistically significant differences observed between the treated and control groups, highlighting its potential in protecting against oxidative stress and cardiac damage.
Additionally, GHRP-6 has shown potential benefits in reducing systolic dysfunction, indicating its protective role against oxidative stress and liver damage.
GHRP-6 and Oxidative Stress
GHRP-6 has garnered attention for its antioxidant properties, which play a vital role in protecting against oxidative stress and cellular damage. Oxidative stress occurs when the body’s antioxidant defenses are overwhelmed by reactive oxygen species (ROS), leading to cell damage and contributing to various diseases. GHRP-6 has been shown to reduce ROS levels and enhance antioxidant defenses, suggesting its potential in mitigating oxidative stress-related conditions.
In a notable study, GHRP-6 was found to reduce myocardial necrosis and improve cardiac function in rats with acute myocardial infarction. The treatment with GHRP-6 led to a significant reduction in ROS levels and an increase in antioxidant defenses in the heart, highlighting its potential in protecting against oxidative stress and cardiac damage.
Another study demonstrated that GHRP-6 could reduce liver fibrosis in chronically intoxicated rats. The peptide treatment resulted in lower ROS levels and enhanced antioxidant defenses in the liver, indicating its protective role against oxidative stress and liver damage.
Overall, the evidence suggests that GHRP-6 may be a valuable therapeutic agent for conditions associated with oxidative stress, such as growth hormone deficiency, cardiotoxicity, and liver disease. Its ability to reduce ROS levels and bolster antioxidant defenses positions GHRP-6 as a promising candidate for further research and potential clinical applications.
GHRP-6 can be purchased from Loti Labs. It is important to buy USA made peptides to ensure the integrity of your research. GHRP-6 sold from Loti Labs is tested through HPLC and Mass spectrometry to ensure quality. GHRP-6 is commonly sold in 5mg vials. It is available in lyophilized powder form.
References
Bresson-Bepoldin L, Dufy-Barbe L. GHRP6-stimulated hormone secretion in somatotrophs: involvement of intracellular and extracellular calcium sources. J Neuroendocrinol. 1996;8(4):309–314. doi:10.1046/j.1365-2826.1996.04608.x
Settembrini B, Figueroa J, Gallardo M, Chiocchio S. Growth Hormone (GH) but not IGF-I-Secretion is Stimulated in Aged Rats by Chronic Hexarelin and GHRP-6 administration. Endocr Regul. 1998;32(1):17–26.
Mendoza Marí Y, Fernández Mayola M, Aguilera Barreto A, et al. Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plast Surg Int. 2016;2016:4361702. doi:10.1155/2016/4361702
